355836-20-3Relevant academic research and scientific papers
Discovery of N -(1-ethylpropyl)-[3-methoxy-5-(2-methoxy-4- trifluoromethoxyphenyl)-6-methyl-pyrazin-2-yl]amine 59 (NGD 98-2): An orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist
Hodgetts, Kevin J.,Ge, Ping,Yoon, Taeyoung,Lombaert, Stéphane De,Brodbeck, Robbin,Gulianello, Michael,Kieltyka, Andrzej,Horvath, Raymond F.,Kehne, John H.,Krause, James E.,Maynard, George D.,Hoffman, Diane,Lee, Younglim,Fung, Laurence,Doller, Dario
, p. 4187 - 4206 (2011/08/21)
The design, synthesis, and structure-activity relationships of a novel series of pyrazines, acting as corticotropin releasing factor-1 (CRF-1) receptor antagonists, are described. Synthetic methodologies were developed to prepare a number of substituted p
5-SUBSTITUTED-2-ARYLPYRAZINES AS MODULATORS OF CRF RECEPTORS
-
Page 39, (2010/02/06)
Novel 5-substituted-2-arylpyrazine compounds are provided. Such compounds can act as selective modulators of CRF receptors. The 5-substituted-2-arylpyrazine compounds provided herein are useful in the treatment of a number of CNS and peripheral disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds provided are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.
SUBSTITUTED ARYLPYRAZINES
-
, (2008/06/13)
Arylpyrazine compounds are provided, including arylpyrazines that can bind with high affinity and high selectivity to CRF1 receptors, including human CRF1 receptors. The invention thus includes methods for treatment of disorders and diseases associated with CRF1 receptors, including CNS-related disorders and diseases, particularly affective disorders and diseases, and acute and chronic neurological disorders and diseases.
